Targeting TBK1 and CARM1 to Combat Lung Adenocarcinoma
Abstract
The overall objective of this proposal is to assess if inhibitors of CARM1, TBK1 or Raf-1, alone or in combination, reduces the viability of lung cancer cells through the downregulation of YAP1. A series of biochemical and in vivo experiments will be conducted to assess this. Experiments will also be conducted to elucidate these drugs or their combinations, affects the anti-cancer activity of T-cells in vitro and T-cell infiltration in vivo. The Specific Aims of the study are: Aim 1. To elucidate the molecular mechanisms by which TBK1 and CARM1 modulate the growth and metastasis of lung adenocarcinoma and Aim 2. To test the efficacy of TBK1 and CARM1 inhibitors in targeting K-Ras mutant lung cancer.
Document Details
- Document Type
- Technical Report
- Publication Date
- Aug 01, 2021
- Accession Number
- AD1168860
Entities
People
- Srikumar Chellappan
Organizations
- H. Lee Moffitt Cancer Center & Research Institute